Rapid tuberculosis test Xpert® MTB/RIF Ultra

for antibodiesMycobacterium tuberculosis

Globally in 2019, an estimated 10.0 million people fell ill with TB. There were 1.4 million TB deaths (14% among HIV-positive people).1 Today, the challenge to the global TB community is to ‘End TB’. The reliance on microscopy, with a sensitivity of only 46%–78%,2 is a severe limitation. Between 36%–59% of pulmonary TB cases are smear-negative/culture-positive and the relative transmission rate (10-24%) of these patients has a strong impact on patient management in hospitals, as well as TB control programs in developed and developing countries.3,4 In order to support the goal of TB elimination, we must implement efficient active case finding. A precise and early detection of TB is needed to improve case management and significantly enhance prevention of TB transmission. The Solution Enhancing the Standard Xpert MTB/RIF revolutionized the management of Mycobacterium tuberculosis (MTB) infections by providing faster and more accurate MTB diagnosis that detects MTB and rifampicin (RIF) resistance simultaneously. Following World Health Organization endorsement in 2010, Xpert MTB/RIF has helped improve TB programs in over 130 countries and counting. Building on this success, faster and more accurate detection of MTB from the first point of encounter in the community is critical. Partnered with GeneXpert® Systems, Xpert MTB/RIF Ultra will bring: Improved performance and faster time to result Higher sensitivity especially in smear-negative TB cases Increased accuracy of Rifampicin results Improved detection of mixed infections Same easy-to-use process